BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28617578)

  • 1. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.
    Rao TD; Fernández-Tejada A; Axelrod A; Rosales N; Yan X; Thapi S; Wang A; Park KJ; Nemieboka B; Xiang J; Lewis JS; Olvera N; Levine DA; Danishefsky SJ; Spriggs DR
    ACS Chem Biol; 2017 Aug; 12(8):2085-2096. PubMed ID: 28617578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
    PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
    Thomas D; Sagar S; Liu X; Lee HR; Grunkemeyer JA; Grandgenett PM; Caffrey T; O'Connell KA; Swanson B; Marcos-Silva L; Steentoft C; Wandall HH; Maurer HC; Peng XL; Yeh JJ; Qiu F; Yu F; Madiyalakan R; Olive KP; Mandel U; Clausen H; Hollingsworth MA; Radhakrishnan P
    Mol Ther; 2021 Apr; 29(4):1557-1571. PubMed ID: 33359791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
    PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
    Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
    Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia.
    Giamougiannis P; Martin-Hirsch PL; Martin FL
    Carcinogenesis; 2021 Apr; 42(3):327-343. PubMed ID: 33608706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.
    Das S; Majhi PD; Al-Mugotir MH; Rachagani S; Sorgen P; Batra SK
    Sci Rep; 2015 Jun; 5():9759. PubMed ID: 26044153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
    Bruney L; Conley KC; Moss NM; Liu Y; Stack MS
    Biol Chem; 2014 Oct; 395(10):1221-31. PubMed ID: 25205731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
    Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
    Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    Matte I; Garde-Granger P; Bessette P; Piché A
    BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Sharma SK; Mack KN; Piersigilli A; Pourat J; Edwards KJ; Keinänen O; Jiao MS; Zhao H; White B; Brooks CL; de Stanchina E; Madiyalakan MR; Hollingsworth MA; Radhakrishnan P; Lewis JS; Zeglis BM
    Clin Cancer Res; 2022 Mar; 28(5):948-959. PubMed ID: 34907079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
    Stasenko M; Smith E; Yeku O; Park KJ; Laster I; Lee K; Walderich S; Spriggs E; Rueda B; Weigelt B; Zamarin D; Rao TD; Spriggs DR
    Sci Rep; 2021 Feb; 11(1):3718. PubMed ID: 33580170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
    Dharma Rao T; Park KJ; Smith-Jones P; Iasonos A; Linkov I; Soslow RA; Spriggs DR
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):462-72. PubMed ID: 20453816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.
    Giannakouros P; Matte I; Rancourt C; Piché A
    Int J Oncol; 2015 Jan; 46(1):91-8. PubMed ID: 25338620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel monoclonal antibody to a defined peptide epitope in MUC16.
    Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
    Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
    Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
    Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of binding epitopes of CA125 monoclonal antibodies.
    Marcos-Silva L; Narimatsu Y; Halim A; Campos D; Yang Z; Tarp MA; Pereira PJ; Mandel U; Bennett EP; Vakhrushev SY; Levery SB; David L; Clausen H
    J Proteome Res; 2014 Jul; 13(7):3349-59. PubMed ID: 24850311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC16: molecular analysis and its functional implications in benign and malignant conditions.
    Haridas D; Ponnusamy MP; Chugh S; Lakshmanan I; Seshacharyulu P; Batra SK
    FASEB J; 2014 Oct; 28(10):4183-99. PubMed ID: 25002120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.
    Reinartz S; Failer S; Schuell T; Wagner U
    Eur J Cancer; 2012 Jul; 48(10):1558-69. PubMed ID: 21852110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC16 promotes EOC proliferation by regulating GLUT1 expression.
    Wang F; Zhang Q; Zhang H; Qiao X; Zhang X; Zhang K; Gu X; Wang L; Cui J
    J Cell Mol Med; 2021 Mar; 25(6):3031-3040. PubMed ID: 33543559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.